SCHEMBL2197786

SCHEMBL2197786

NCC(=O)N[C@@H](Cc1cnc[nH]1)C(=O)O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC15A2 Q16348 1/20 0.72
ITGB2 P05107 3/20 0.58
ICAM1 P05362 3/20 0.58
ITGAL P20701 3/20 0.58
CA1 P00915 3/20 0.58
CA2 P00918 3/20 0.58
SLC6A5 Q9Y345 1/20 0.58
CYP3A4 P08684 2/20 0.57
SLC7A5 Q01650 1/20 0.57
CPB2 Q96IY4 1/20 0.53
EPHX2 P34913 1/20 0.53
AGTR2 P50052 1/20 0.50
ALDH1A1 P00352 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C19 P33261 1/20 0.47
PRSS1 P07477 1/20 0.47
PRSS2 P07478 1/20 0.47
PRSS3 P35030 1/20 0.47
HIF1A Q16665 1/20 0.47
GGT1 P19440 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30081493 1.00 SLC15A2 (0.72) SLC15A2ITGB2ICAM1ITGALCA1
SCHEMBL30572128 0.91 SLC15A2 (0.62) SLC15A2ITGB2ICAM1ITGALCA1
SCHEMBL29350066 0.91 SLC15A2 (0.62) SLC15A2ITGB2ICAM1ITGALCA1
Carnosine SCHEMBL1160796 0.89 SLC15A2 (0.63) SLC15A2ITGB2ICAM1ITGALCA1
Carnosine SCHEMBL22392772 0.89 SLC15A2 (0.63) SLC15A2ITGB2ICAM1ITGALCA1
Carnosine SCHEMBL1161102 0.89 SLC15A2 (0.63) SLC15A2ITGB2ICAM1ITGALCA1
Carnosine SCHEMBL28181512 0.88 ITGB2 (0.65) SLC15A2ITGB2ICAM1ITGALCA1
Carnosine SCHEMBL27776508 0.88 SLC15A2 (0.61) SLC15A2ITGB2ICAM1ITGALCA1
Carnosine SCHEMBL30129832 0.88 SLC15A2 (0.61) SLC15A2ITGB2ICAM1ITGALCA1
Carnosine SCHEMBL28196655 0.88 SLC15A2 (0.61) SLC15A2ITGB2ICAM1ITGALCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 272 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4659592-A1 FLAVOR ENHANCING COMPOSITION, MANUFACTURING METHOD THEREFOR, AND METHOD FOR ENHANCING FLAVOR OF FOOD PRODUCT House Foods Corporation (JP) 2025-12-10 EP claimed
EP-4659591-A1 TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT House Foods Group Inc. (JP) 2025-12-10 EP claimed
US-20250281603-A1 Compositions for the Treatment of Infectious Disease Related Complications and Methods Thereof AMARANTUS BIOSCIENCE HOLDINGS (US) 2025-09-11 US claimed
US-20250263437-A1 POLYPEPTIDE FOR REPAIRING SKIN WOUND OR MUCOSAL INJURY, AND APPLICATION THEREOF SICHUAN GOODDOCTOR PANXI PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US claimed
WO-2025072741-A1 PRESERVATIVES FOR MOLECULAR SAMPLE ANALYSIS WITH SAMPLE COLLECTION DEVICES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2025-04-03 WO claimed
CN-119060121-B Synthesis method of oligopeptide-1 山东美欣生物科技有限公司 2025-03-14 CN claimed
EP-4504166-A1 TOPICAL FORMULATION FOR USE IN THE TREATMENT OR PREVENTION OF ITCHY DRY SKIN MC2 Therapeutics Limited (GB) 2025-02-12 EP claimed
EP-4469034-A1 COMPOSITION FOR TREATING ESOPHAGEAL REFLUX Metis Healthcare S.r.L. (IT) 2024-12-04 EP claimed
CN-119060121-A Synthesis process of oligopeptide-1 山东美欣生物科技有限公司 2024-12-03 CN claimed
CN-118984702-A Topical preparation for treating or preventing dry skin itch MC2疗法有限公司 2024-11-19 CN claimed
WO-2022074228-A1 TREATMENT OF DERMATOLOGICAL CONDITIONS MC2 THERAPEUTICS LTD (GB) 2022-04-14 WO claimed
CN-106573895-B Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof 特瑞海德公司 2020-11-24 CN claimed
CN-106573895-A Novel 5-acylsulfanyl-histidine compounds as precursors for the corresponding 5-sulfanylhistidines and disulfides thereof 特瑞海德公司 2017-04-19 CN claimed
EP-2262521-B1 OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE WITH A GLYCINE MOIETY BAUSCH & LOMB (US) 2014-02-26 EP claimed
US-7977383-B2 Containing alkali ions, electrolytes, a buffer, polyol, saccharide and hydroxamic acid derivatives DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2011-07-12 US claimed
EP-2262521-A1 OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE Bausch & Lomb Incorporated (US) 2010-12-22 EP claimed
EP-1859679-B1 Protective solution for preventing ischaemia damage KOEHLER CHEMIE DR FRANZ (DE) 2009-10-28 EP claimed
WO-2009120562-A1 OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE BAUSCH & LOMB INCORPORATED (US) 2009-10-01 WO claimed
US-20090247469-A1 OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE BAUSCH HEALTH AMERICAS, INC. 2009-10-01 US claimed
US-20030215781-A1 Protective solutions for organs DR. FRANZ KOEHLER CHEMIE GMBH (DE) 2003-11-20 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247469-A1 OPHTHALMIC COMPOSITIONS COMPRISING A DIPEPTIDE GPKOW, GLMN, ARGLU1 SLC15A2 3239/4885ITGB2 4012/4885ICAM1 1568/4885
US-20030215781-A1 Protective solutions for organs GLS, CA1, SI SLC15A2 457/4885ITGB2 3782/4885ICAM1 1990/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.